Efranat Raises $4.5M To Continue Trials On GcMAF Cancer Drug

November 19, 2014 | The Israeli company Efranat, which has developed a cancer treatment, raised $4.5 million from Battery Ventures and others. The company’s cancer treatment, which is currently undergoing trials, makes use of the controversial substance GcMAF, which was touted by an American professor as a substance that could ‘completely heal’ cancer, research that has since been discredited by a number of medical institutions. Efranat hopes to show that GCMAF can indeed be used to treat and even cure cancer, conducting tests on animals (dogs to be specific) and humans that have proven successful thus far. Following the trials, Efranat hopes to market the treatment as technology that engages the patient’s own immune system to fend off cancer.